Episode Details:
Our Guest: Spiro Rombotis, CEO at Cyclacel Pharmaceuticals
What you’ll get out of this episode:
- Rombotis’s background and an overview of Cyclacel
- Which part of the cell cycle they’re targeting?
- What their leading candidates are, and the current clinical trial statuses of each.
- What makes their CDK inhibitor strategy unique compared to other biopharmaceutical companies?
- Their PLK1 program
- Near-term milestones and what’s next?
Watch
Listen
WORD FROM OUR SPONSORS:
Our sponsor for this episode are Sage Growth Partners.
Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media – @sagegrowthpartners
Learn more about Cyclacel Pharmaceuticals follow these links:
Also, be sure to follow Slice of Healthcare on our social channels:
– Website – LinkedIn – Twitter – YouTube – Newsletter
